Dose variations in tumor volumes and organs at risk during IMRT for head-and-neck cancer
- PMID: 23149770
- PMCID: PMC5718549
- DOI: 10.1120/jacmp.v13i6.3723
Dose variations in tumor volumes and organs at risk during IMRT for head-and-neck cancer
Abstract
Many head-and-neck cancer (HNC) patients treated with radiotherapy suffer significant anatomical changes due to tumor shrinkage or weight loss. The purpose of this study was to assess dose changes over target volumes and organs at risk during intensity-modulated radiotherapy for HNC patients. Sixteen HNC IMRT patients, all requiring bilateral neck irradiation, were enrolled in the study. A CTplan was performed and the initial dose distribution was calculated. During the treatment, two subsequent CTs at the 15th (CT15) and 25th (CT25) fractions were acquired. The initial plan was calculated on the CT15 and CT25, and dose-volume differences related to the CTplan were assessed. For target volumes, mean values of near-maximun absorbed dose (D2%) increased at the 25th fraction, and doses covering 95% and 98% of volume decreased significantly at the 15th fraction. Contralateral and ipsilateral parotid gland mean doses increased by 6.1% (range: -5.4, 23.5%) and 4.7% (range: -9.1, 22.3%), respectively, at CT25. The D2% in the spinal cord increased by 1.8 Gy at CT15. Mean absorbed dose increases at CT15 and CT25 were observed in: the lips, 3.8% and 5.3%; the oral cavity, 3.5% and 2.5%; and lower middle neck structure, 1.9% and 1.6%. Anatomical changes during treatment of HNC patients affect dose distribution and induce a loss of dose coverage to target volumes and an overdosage to critical structures. Appropriate organs at risk have to be contoured and monitored in order to know if the initial plan remains suitable during the course of the treatment. Reported dosimetric data can help to identify patients who could benefit from adaptive radiotherapy.
Similar articles
-
Volume changes during head-and-neck radiotherapy and its impact on the parotid dose - A single-institution observational study.J Cancer Res Ther. 2020 Apr-Jun;16(3):575-580. doi: 10.4103/jcrt.JCRT_589_19. J Cancer Res Ther. 2020. PMID: 32719270
-
A Study to Assess the Dosimetric Impact of the Anatomical Changes Occurring in the Parotid Glands and Tumour Volume during Intensity Modulated Radiotherapy using Simultaneous Integrated Boost (IMRT-SIB) in Head and Neck Squamous Cell Cancers.Cancer Med. 2021 Aug;10(15):5175-5190. doi: 10.1002/cam4.4079. Epub 2021 Jun 22. Cancer Med. 2021. PMID: 34159749 Free PMC article.
-
Adaptive Radiotherapy for Head and Neck Cancer.Technol Cancer Res Treat. 2017 Apr;16(2):218-223. doi: 10.1177/1533034616662165. Epub 2016 Aug 19. Technol Cancer Res Treat. 2017. PMID: 27502958 Free PMC article.
-
Adaptive radiotherapy for head and neck cancer.Acta Oncol. 2018 Oct;57(10):1284-1292. doi: 10.1080/0284186X.2018.1505053. Epub 2018 Oct 5. Acta Oncol. 2018. PMID: 30289291 Review.
-
New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting.Semin Oncol. 2008 Jun;35(3):236-50. doi: 10.1053/j.seminoncol.2008.03.003. Semin Oncol. 2008. PMID: 18544439 Free PMC article. Review.
Cited by
-
Advances in Image-Guided Radiotherapy in the Treatment of Oral Cavity Cancer.Cancers (Basel). 2022 Sep 23;14(19):4630. doi: 10.3390/cancers14194630. Cancers (Basel). 2022. PMID: 36230553 Free PMC article. Review.
-
Evaluating the dosimetric effect of treatment-induced changes in virally mediated head and neck cancer patients.J Med Radiat Sci. 2013 Dec;60(4):139-44. doi: 10.1002/jmrs.30. Epub 2013 Nov 20. J Med Radiat Sci. 2013. PMID: 26229622 Free PMC article.
-
A Preliminary Simulation Study of Dose-Guided Adaptive Radiotherapy Based on Halcyon MV Cone-Beam CT Images With Retrospective Data From a Phase II Clinical Trial.Front Oncol. 2020 Sep 29;10:574889. doi: 10.3389/fonc.2020.574889. eCollection 2020. Front Oncol. 2020. PMID: 33134173 Free PMC article.
-
Prospects for online adaptive radiation therapy (ART) for head and neck cancer.Radiat Oncol. 2024 Jan 8;19(1):4. doi: 10.1186/s13014-023-02390-6. Radiat Oncol. 2024. PMID: 38191400 Free PMC article.
-
Optimal timing of organs-at-risk-sparing adaptive radiation therapy for head-and-neck cancer under re-planning resource constraints.Phys Imaging Radiat Oncol. 2025 Jan 27;33:100715. doi: 10.1016/j.phro.2025.100715. eCollection 2025 Jan. Phys Imaging Radiat Oncol. 2025. PMID: 40123771 Free PMC article.
References
-
- Huang D, Xia P, Akazawa P, et al. Comparison of treatment plans using intensity‐modulated radiotherapy and three‐dimensional conformal radiotherapy for para‐nasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2003;56(1):158–68. - PubMed
-
- Chao KS, Ozyigit G, Blanco AI, et al. Intensity‐modulated radiation therapy for oropharyngeal carcinoma: Impact of the tumor volume. Int J Radiat Oncol Biol Phys. 2004;59(1):43–50. - PubMed
-
- Miles EA, Clark CH, Urbano MT, et al. The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiother Oncol. 2005;77(3):241–46. - PubMed
-
- Scott‐Brown M, Miah A, Harrington K, Nutting C. Evidence‐based review: Quality of life following head and neck intensity‐modulated radiotherapy. Radiother Oncol. 2010;97(2):249–57. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials